ArticleBlood cancer journal2025

Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers.

Timothy J Voorhees et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.